| Vardenafil: Efficacy, Tolerability and Future Directions - Abstract |
|
|
|
|
|
| Friday, 19 June 2009 | ||
|
Urology Service, Walter Reed Army Medical Center, Urology Clinic-4F, 6900 Georgia Avenue, NW, Washington, DC 20307, USA. This email address is being protected from spam bots, you need Javascript enabled to view it Vardenafil is a short-acting PDE5 inhibitor used in the treatment of male erectile dysfunction. It is the most potent and specific of the three commercially available PDE5 inhbitors, which may decrease incidence of side effects, although this has not been demonstrated clinically. Although its efficacy in the treatment of erectile dysfunction has been demonstrated in several studies, recent and continuing studies have shown vardenafil's promise as an effective agent in penile rehabilitation, decreasing lower urinary tract symptoms resulting from benign prostatic hyperplasia and management of pulmonary hypertension. Written by: Reference: PubMed Abstract UroToday.com Erectile Dysfunction (ED) Section
Please log-in or register in order to submit comments. Powered by AkoComment! |
||
| < Prev | Next > |
|---|
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2009 UroToday ® All Rights Reserved |











